Algorae Pharmaceuticals Ltd ADR LVCLY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.05
- Day Range
- $0.04–0.05
- 52-Week Range
- $0.02–0.08
- Bid/Ask
- $0.02 / $0.06
- Market Cap
- $7.09 Mil
- Volume/Avg
- 2,300 / 10,220
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer’s disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 48
- Website
- https://www.algoraepharma.com
Valuation
|
Metric
|
LVCLY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LVCLY
|
|---|---|
Quick Ratio | 26.81 |
Current Ratio | 26.81 |
Interest Coverage | — |
Quick Ratio
LVCLY
Profitability
|
Metric
|
LVCLY
|
|---|---|
Return on Assets (Normalized) | −60.91% |
Return on Equity (Normalized) | −66.76% |
Return on Invested Capital (Normalized) | −69.26% |
Return on Assets
LVCLY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pchvwllvb | Tnvmy | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wtdffbvn | Xjlhvj | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dlkdytfr | Xffgdd | $99.6 Bil | |
MRNA
| Moderna Inc | Swmbcypn | Wnck | $38.8 Bil | |
ARGX
| argenx SE ADR | Rkgvmmkf | Msd | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Hwqlwffc | Bxjw | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vspvbhk | Cznkq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nkkxjrng | Xxcbrzd | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lmrvxghxpj | Qjkfgh | $12.4 Bil | |
INCY
| Incyte Corp | Wsxdjmt | Jlfbjkz | $11.9 Bil |